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Abstract
Background: To study the impact of psoriasis and features associated with psoriasis on classification and outcome
in a population-based follow-up cohort of children with juvenile idiopathic arthritis (JIA).
Methods: In all, 440 children with JIA were followed for a median of 8 years in a prospective Nordic population-based
cohort study. Data for remission was available for 427 of these children. The presence of psoriasis, psoriasis-like rash,
dactylitis, nail pitting, enthesitis, tenosynovitis and heredity was assessed in relation to ILAR classification and remission.
Results: Clinical findings associated with psoriasis developed consecutively during the 8-year period. Six of 14 children
with psoriasis were not classified as juvenile psoriatic arthritis according to the ILAR criteria at 8 year follow-up.
Dactylitis was more common in children with early onset of JIA. After 8 years we found a cumulative median
number of eleven arthritic joints in children with psoriasis or psoriasis-like rash compared with six in the rest of
the cohort (p = 0.02). Also, the chance for not being in remission after 8 years increased significantly in patients
with psoriasis, psoriasis-like rash or at least two of: 1) first-degree heredity for psoriasis or psoriatic arthritis, 2)
dactylitis or 3) nail pitting, compared with the rest of the group (OR 3.32, p = 0.010).
Conclusions: Our results indicate a more severe disease over time in psoriasis-associated JIA, as features of psoriasis
develop during the disease course. This group is a major challenge to encompass in a future JIA classification in order
to facilitate early tailored treatment.
Keywords: Arthritis, Juvenile Rheumatoid, Psoriasis, Child
Background
Classification of children with JIA and features of psoriasis
has challenged the research community for decades. The
disease comprises a variety of features often developing
over the years, with large heterogeneity. Since classifica-
tion criteria have varied over time there have also been
dissimilarities in the cohorts studied. The question has
been raised whether juvenile psoriatic arthritis (JPsA) is
an entity of its own [1] or whether psoriasis and juvenile
arthritis develop only as separate entities [2–4]. Adult
psoriatic arthritis (PsA) is considered a unique disease
entity, clearly distinct from rheumatoid arthritis. Im-
munology research has revealed that molecules of the
interleukin-23 and interleukin-17 pathways promote
skin and joint inflammation in psoriasis [5]. These dis-
coveries have led to efforts to target interleukin-23,
interleukin-17 and related molecules to treat psoriasis
and psoriatic arthritis [6].
Classification of JPsA has been a challenge. In 1989, the
Vancouver criteria for JPsA were presented comprising
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two categories of JPsA, one definite and one probable [7].
In three studies utilizing the Vancouver classification
criteria, joint patterns differed at onset between oligoar-
ticular JIA and oligoarticular JPsA, with greater involve-
ment of small joints in the hands and wrists being
more typical in the latter category [1, 8, 9]. Age at onset
was significantly higher in oligoarticular JPsA compared
with oligoarticular JIA. A child with an oligoarticular
pattern with wrists or small joints in hands or feet
affected, more often had nail pitting, psoriasis or hered-
ity for psoriasis.
In the current ILAR classification, JPsA may be diag-
nosed in children with arthritis and (1) psoriasis or (2)
if two features suggestive of a psoriatic diathesis are
present, including dactylitis, nail changes, or psoriasis
in a first-degree relative, in the absence of specific
exclusions [10].
During later years two distinct phenotypic subgroups
of JPsA have been discussed. One occurs in children
(predominantly girls) younger than 5 years of age at on-
set, with small joint involvement, a higher risk of pro-
gression to polyarticular disease, high frequency of ANA
positivity and dactylitis. In contrast, children above 5
years of age at onset had no obvious gender difference,
were more likely to be ANA negative and to exhibit
enthesitis and axial joint involvement [7, 11, 12].
So far, the prognosis for JPsA has been considered ap-
proximately the same as for patients with other categories
of JIA based on two follow-up studies, one using both the
Vancouver and the ILAR criteria with a follow-up time of
1 month, up to 16.8 years [2] and the second using the
Vancouver criteria with a median follow-up time of 2
years [13]. Children with a polyarticular course had the
worst prognosis. Positive ANA in children with JPsA has
been discussed as a negative prognostic factor without any
conclusive results [7, 9, 14]. Occurrence of HLA-B27 has
been shown as a risk factor for sacroiliitis in JPsA [2].
In light of this knowledge, we wanted to challenge
earlier findings by studying a well-defined cohort of chil-
dren with JIA, followed prospectively over a long time,
especially since previous studies were referral-based.
Our aim was to study the occurrence of variables indi-
cating psoriatic diathesis during the first 8 years of dis-
ease in a population-based cohort of children with JIA
and to address aspects of classification and outcome.
Methods
Patients were recruited from a Nordic JIA cohort. All
new patients with JIA from defined geographical areas of
Denmark, Finland, Norway, and Sweden were collected
prospectively during 1997–2000 [15]. The study design
was population-based. All physicians within each catch-
ment area eligible to meet children with arthritis re-
ceived a letter informing about the study. Pediatric
rheumatologists from 12 participating centers included
patients. The database consisted of clinical and labora-
tory data from 500 patients, including 440 followed for
at least 7 years, median 98 months. The 60 patients lost
to follow-up did not differ from the 440 with follow-up
data as regards number of active joints during the first 6
months after onset, Childhood Health Assessment Ques-
tionnaire (CHAQ), Juvenile Arthritis Disease Activity
Score (JADAS27), or proportion with oligoarticular dis-
ease at baseline. Also, occurrence of psoriasis, psoriatic-
like rash, dactylitis, enthesitis, first degree heredity for
psoriasis or psoriatic arthritis did not differ between the
60 lost to follow-up compared to the 440 in the study
cohort. JIA categories had been determined based on the
ILAR criteria [10]. For 427 of 440 children, outcome
data was available for analysis of remission. The pres-
ence of psoriasis and psoriasis-like rash during the 8-
year follow-up period was assessed in relation to clin-
ical characteristics, ILAR classification and remission.
Remission status according to the preliminary criteria
of Wallace et al was used [16]. Clinical variables were
collected cumulatively during this period; they were not
necessarily present at the time of the 8-year follow-up.
A patient was considered to have psoriasis if a derma-
tologist had made that diagnosis. Rashes noted by the
examining rheumatologist, well skilled in pediatric
rheumatology, and thought likely (but not definitely) to
represent psoriasis were considered psoriasis-like.
Results
In the cohort of 440 children followed for at least 7 years
after disease onset (median 98 months, range 84–147
months), 14 children developed psoriasis and 13 psoriasis-
like rash (Table 1). Only 8 of the 14 children with psoriasis
and JIA were classified as juvenile psoriatic arthritis (JPsA)
according to the ILAR criteria. The other six were classi-
fied as undifferentiated. Four of those were mutually
excluded from JPsA as well as enthesitis related arth-
ritis (ERA), thus they did not fit any category. One boy
was excluded because he was older than six at onset
and HLA-B27 positive, and another child was excluded
because of positive rheumatoid factor (RF). Children
with dactylitis and/or nail pitting were found among
many ILAR categories. First-degree heredity for psoria-
sis or psoriatic arthritis occurred in 9 of 14 children
with JPsA and in 51 of 57 of children classified as
undifferentiated arthritis. In a comparison between the
eight children with psoriasis, classified as JPsA (ILAR
criteria) at 98 months of disease, and the six children
with psoriasis classified as undifferentiated, there was
no significant difference in age at onset (p = 0.34), first
degree heredity for psoriasis/psoriatic arthritis (p = 0.53),
dactylitis (p = 1.0), nail pitting (p = 0.30) or cumulative
number of joints (p = 0.59), but the cohorts were too
Ekelund et al. Pediatric Rheumatology  (2017) 15:13 Page 2 of 7
small for meaningful statistical analyses. Children with
psoriasis (n = 14) compared to those with psoriatic-like
rash (n = 13) did not differ regarding gender (p = 0.71),
outcome (p = 0.16) or median cumulative number of
joints (p = 0.26).
Table 2 presents the development of clinical features
associated with psoriasis during the first 8 years of dis-
ease. Twenty-four children developed dactylitis during
disease course, 15 of them had dactylitis at onset.
Median age at time of onset of JIA in the group with
dactylitis was 2.4 (IQR 1.7–5.4) years compared with 5.8
(IQR 2.7–9.9) years in the rest of the cohort (p = 0.007).
Five of 24 children with dactylitis developed psoriasis
or psoriasis-like rash during the first 8 years of their
arthritis, Table 3. Table 3 also presents the significantly
higher cumulative number of active joints in children
with psoriasis or psoriasis-like rash as well as the
increased frequency of dactylitis, nail pitting, enthesitis,
and first-degree heredity for psoriasis compared with
children without psoriasis or psoriasis-like rash.
Features of sacroiliitis (SI) developed in several chil-
dren with psoriasis or psoriasis- like rash (Table 4). SI or
enthesitis coexisting with psoriasis or psoriasis-like rash
lead to mutual exclusion from both JPsA and ERA
categories.
Seven of 27 children with psoriasis or psoriasis-like
rash were HLA-B27 positive (missing value in another
three) and this group had a high age of onset (median
10.8, IQR 5.9–11.8 years), and a high cumulative number
of joints (median 15, IQR 9–18 joints), data not shown.
Several of the ERA or SI-like features were clustered to-
gether. Six of the 27 children with psoriasis or psoriasis-
like rash had inflammatory back pain or buttock pain at
any time during the first 98 months of disease (Table 4),
three of those were HLA-B27 positive, and in two
sacroiliitis was confirmed by x-ray.
In children with psoriasis or psoriasis-like rash or at
least two of either dactylitis, nail pitting, or first-degree
heredity of psoriasis, the remission rate was signifi-
cantly lower compared with children without these
clinical features, p = 0.010 (Table 5).
First-degree heredity for psoriasis in children with
oligoarticular onset did not increase the risk for
oligoarticular extended disease during those first 8 years
of disease (data not shown).
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences, version 23 (SPSS Inc., Chicago,
IL, USA). Demographics and disease characteristics were
described using median and interquartile range (IQR), or
total number and percent of study cohort. Statistical ana-
lyses of differences between children with and without
psoriasis/psoriasis-like rash during the first year of disease
were performed using the chi-square test (Fisher’s exact
test, 2-sided) for comparison of dichotomous variables.
The Mann-Whitney U-test was used for comparison of
non-parametric data and independent samples was used
for comparison of median values between the two groups.
Table 1 Clinical characteristics in a Nordic cohort of children with juvenile idiopathic arthritis, classified according to the ILAR

















for psoriasis or psoriatic
arthritis n (%)
Systemic arthritis 18 4.5 (2.2-6.7) - - - - 18 -
Oligoarticular persistent 133 5.1 (2.6-8.5) - 1 6 3 123 -
Oligoarticular extended 78 4.1 (1.8-8.4) - 2 1 3 74 -
Polyarticular RF negative 80 4.9 (2.2-9.1) - 2 7 - 79 -
Polyarticular RF positive 3 10.2, 13.2, 13.3 - - - - 3 -
Psoriatic arthritis 14 5.8 (4.3-7.9) 8 3 3 7 14 9 (64.3)
Enthesitis-related arthritis 49 10.0 (6.8-12.3) - 3 1 2 47 -
Undifferentiated arthritis 65 7.8 (3.2-11.8) 6a 2 6 3 57 51 (78.5)
aNone of the six patients with psoriasis at the 8-year follow-up fit any category, four because of mutual exclusion from JPsA and ERA because of enthesitis, one
because he was a HLA-B27-positive boy older than 6 years at onset, one because of positive RF
bInternational League of Associations for Rheumatology classification criteria [10] assessed at last study visit (median 98, range 84–147 months)
Table 2 Development of clinical features associated with
psoriasis in 440 children with JIA followed for at least seven
years after onset (median 98, range 84–147 months)
Clinical features Patients at onset n Cumulative number
of patients at eight years n
Dactylitis 15 24
Nail pitting 10 18
Psoriasis 11 14
Psoriasis-like rash 6 13
Enthesitis 37 41
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Binary logistic regression analyses were performed in
order to identify the association between occurrence of
psoriasis or psoriasis-like rash and failure of remission 8
years after disease onset. The dichotomized variable
remission (remission without medication) versus remis-
sion with medication or not in remission was used as
the dependent variable in the regression model. Results
of the regression analyses are shown as odds ratios (OR),
95% confidence intervals (CI) and p-values. The level of
significance was set at 5% (p < 0.05).
Discussion
In this population-based study of 440 patients followed
for a median of 98 months, we found that as many as
six of 14 children with definite psoriasis were classified
as undifferentiated JIA based on exclusion criteria in the
ILAR classification. In children with psoriasis or
psoriasis-like rash we found a strong association with
first-degree heredity for psoriasis or psoriatic arthritis,
dactylitis and nail pitting, but also with enthesitis. Psor-
iasis or psoriasis-like rash was also associated with
higher cumulative number of active joints and possibly
with less favorable outcome, as features of psoriasis are
additive.
A strength of our study was the prospective
population-based design and also that the whole cohort
was followed for at least 7 years. A weakness was that
the group of children with psoriasis or psoriasis-like rash
was small and no dermatologist verified the psoriasis-
like rash. The pediatric rheumatologists involved in the
study all had several years’ experience and a psoriasis-
like rash was only defined if there was a high suspicion
of psoriasis.
Another clinical sign, dactylitis, has proven a strong
predictor of JPsA [13]. In preparative studies for classifi-
cation of psoriatic arthritis in adults (CASPAR criteria),
the specificity of dactylitis was shown to be 95%, nail
dystrophy 98% and tender enthesitis and diffuse enthesitis
pain 77–93% [17]. The strong association between psori-
atic arthritis, dactylitis, nail changes and enthesitis is in ac-
cordance with our results. In our study cohort occurrence
of dactylitis was spread among ILAR categories, but had a
strong association with psoriasis or psoriasis-like rash.
Also, enthesitis showed a strong association with psoriasis
or psoriasis-like rash in our study cohort. Although enthe-
sitis is a well-recognized feature of PsA in adults, it is an
exclusion criterion for JPsA in the ILAR classification, and
a common reason for exclusion from the JPsA category
[15]. Another important feature in psoriatic diathesis in
adults is heredity for psoriasis [17] and our results pointed
in the same direction.
In our cohort, first-degree heredity for psoriasis was
common in the undifferentiated JIA category, which has
Table 3 Clinical features describing the first eight years of disease in 440 children with JIA according to occurrence of psoriasis or
psoriasis-like rash
Clinical feature Number of patients
assessed
Total cohort Psoriasis or psoriasis-like
rash n = 27
No psoriasis or psoriasis-like
rash n = 413
p-value*
Gender, n (% females) 440 (66.1) 440 (66.1) 27 (48.1) 413 (67.3) 0.06a
Age at time of onset median (IQR) 440 5.5 (2.5-9.7) 7.2 (3.8-11.0) 5.3 (2.3-9.4) 0.08b
Cumulative joints median (IQR) 440 6 (2-12) 11 (5-16) 6 (2-12) 0.02c
Dactylitis (%) 440 24 5 (18.5) 19 (4.6) 0.01a
Nail pitting (%) 440 18 7 (25.9) 11 (2.7) <0.001a
First-degree heredity for psoriasis or
psoriatic arthritis (%)
420 51 7 (25.9) 44 (10.6) 0.03a
Enthesitis (%) 438 41 6 (22.2) 35 (8.5) 0.03a
Tenosynovitis (%) 436 88 6 (22.2) 82 (19.8) 0.81a
*Patients with psoriasis or psoriasis-like rash compared with those without, aFisher’s exact test, bIndependent samples Mann-Whitney U test, cIndependent samples
median test
Table 4 Development of clinical variables during a follow-up
time of at least seven years after onset (median 98, range 84–147





n = 27 na n = 24 na
Radiological SIb
At onset 0
Cumulative at median 98 months 2 0
Inflammatory back pain/buttock pain
At onset 3 0
Cumulative at median 98 months 6 0
Enthesitis
At onset 5 3
Cumulative at median 98 months 6 4
aNumber of patients with the feature developing during the first median
98 months
bSI sacroiliitis
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also been discussed by others and illustrates the classifi-
cation difficulties [18]. Stoll et al studied classification of
juvenile psoriatic arthritis and found that the ILAR cri-
teria excluded almost 60% of those included with the
Vancouver criteria [19], which is in line with our results
regarding ILAR classification.
Another challenge in classification is the progression
of the disease over time. In an earlier publication we
showed that patients classified as JPsA according to the
ILAR criteria increased from 6 to 14 during the follow-
up period. In about half of the children with JPsA, the
classic rash presented after the onset of arthritis, with a
time lag that could be 10 years or more [20]. Manifesta-
tions of psoriasis in the young child are often atypical or
unspecific, such as erythema and scaling behind the ears,
features taken into consideration by the Vancouver set
of JPsA criteria, but excluded under the JIA nomencla-
ture in the ILAR classification [7]. Our data presents the
heterogeneity of JPsA and the development over time of
clinical variables supporting a psoriatic diathesis, as well
as the overlap between JPsA and enthesitis-related arth-
ritis in a group of patients.
The earlier findings of two phenotypic subgroups of
JPsA: a younger group, predominantly girls, with a
polyarticular onset, high frequency of ANA positivity
and dactylitis [13], in contrast to an older age group
more likely to exhibit enthesitis and axial joint involve-
ment [7, 13], can only partly be confirmed by our re-
sults since our cohort was too small for further
analysis. We found a significantly lower age at time of
onset in children who developed dactylitis during the 8
years, compared with those who did not. None of the
15 children with dactylitis at disease onset developed
inflammatory back pain during the disease course and
in the extended group of 24 children with dactylitis
after 8 years, none developed any sign of sacroiliitis.
This result is consistent with a previous observation
that patients with dactylitis and sacroiliitis tend to be
distinctive phenotypic groups of juvenile psoriatic arth-
ritis [21]. Our finding of an older age at onset in the
group of HLA-B27 positive children with psoriasis or
psoriasis-like rash also supports earlier data, but we
were surprised by the very high cumulative number of
joints with arthritis in this group.
The polyarticular disease progression in children with
psoriasis and arthritis in our study is in line with earlier
studies [7, 9, 12]. Our result indicates a somewhat less
favorable outcome in the cohort of children with psoria-
sis, psoriasis-like rash or at least two well-known fea-
tures characterizing the JPsA group, but our numbers
are too low to analyze each of the clinical features as a
single trait, and larger studies are needed to confirm our
results. The prognosis in JPsA defined according to the
Vancouver classification criteria was not worse com-
pared with other JIA categories in earlier studies [2, 13],
but the time of follow-up varied: 1 month in one study
up to 17 years, and a median of 23 months in the other.
By comparison, our cohort was followed for at least 7
years, with a median of 98 months, and in a population-
based setting.
Since classification of JPsA has changed over time, it
is difficult to compare one study with another and to
properly present outcomes in this group of patients. In
our study clinical findings associated with psoriasis as
Table 5 Analyses of binary logistic regression for not being in remission related to psoriasis and psoriasis-related variables in 427
children with JIA, followed for at least seven years of disease
Number of patients Not in remissionc
after 8 years n (%)
p-value OR 95% confidence
interval
Psoriasis or psoriasis-like rasha Yes 25 19 (76.0) 0.062 2.44 0.96-6.2
No 402 227 (56.5)
Psoriasis or psoriasis-like rash
OR at least two of threeb
Yes 31 25 (80.6) 0.010 3.32 1.33-8.27
No 379 211 (55.7)
Dactylitis Yes 24 16 (66.7) 0.36 1.5 0.63-3.6
No 403 230 (57.1)
Nail pitting Yes 18 13 (72.2) 0.21 1.96 0.69-5.6
No 409 233 (57.0)
Enthesitis Yes 40 29 (72.5) 0.046 2.08 1.01-4.29
No 385 215 (55.8)
First-degree heredity for psoriasis
or psoriatic arthritis
Yes 48 28 (58.3) 0.86 1.1 0.42-2.82
No 361 208 (57.6)
Total 427 181 (42.4)
aData in 13 patients with psoriasis and 12 with psoriasis-like rash
b1) dactylitis, 2) nail pitting, 3) first-degree heredity for psoriasis or psoriatic arthritis
cRemission was defined as inactive disease off medication for at least twelve months in accordance with the preliminary definition of Wallace [16]
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well as first-degree heredity for psoriasis were strongly
associated with children developing psoriasis or psoriasis-
like rash during the first 8 years of disease. Our cohort
also reveals the difficulty of using the ILAR classification
to assign those children. The consequence is that we do
not study children with a psoriatic diathesis specifically,
which would be important in relation to new therapies
under development for JPsA and bringing these children
new treatment possibilities.
Conclusions
We suggest stronger emphasis on the variables of psoriatic
diathesis, and not using strict exclusion criteria in future
follow-up studies of JIA, and to consider this also in future
JIA classifications. We need to better understand how to
predict this category of disease and to be able to tailor
proper treatment for this group of children.
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